JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A

JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A

SSSE:600976
27.10
CNY
+0.09
(+0.33%)
2.07EPS
13.14P/E
4.12BMarket Cap
Mar 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
13.09
11.49
14.94
15.35
17.62
14.11
14.68
15.95
21.73
23.91
27.55
23.03
22.2
20.38
Basic EPS, GAAP
0.63
0.76
0.56
0.42
0.59
0.53
0.6
0.96
2.01
2.68
3.41
2.38
2.37
2.04
Free Cash Flow per Basic Share
0.14
0.5
0.12
0.55
-0.04
0.14
0.03
0.52
1.26
0.97
1.33
0.75
1.15
- -
Dividend per Share
0.39
0.41
0.41
0.22
0.13
0.2
0.21
0.2
0.39
0.81
1.02
1.23
0.93
0.91
Book Value per Share
5.95
6.33
6.39
6.61
7.1
7.44
7.83
8.58
9.65
12.12
14.65
15.88
17.32
17.97
Tangible Book Value per Share
5.92
6.16
6.2
6.43
6.87
7.18
7.56
8.3
9.37
11.85
14.43
15.54
16.88
17.47
Basic Weighted Avg Shares
152
153
153
154
154
153
152
154
152
152
153
152
152
153
Sales/Revenue/Turnover
1,992
1,753
2,281
2,364
2,712
2,161
2,239
2,456
3,299
3,641
4,213
3,505
3,370
3,115
Operating Margin (%)
4.87
6.44
2.34
2.17
2.44
1.78
2.34
2.5
7.16
9.06
8.59
5.75
8.44
9.96
Depreciation Expense
13
14
15
17
19
20
20
21
34
39
40
41
46
- -
Net Income, GAAP
96
116
86
65
91
81
91
148
305
408
521
362
360
312
Effective Tax Rate (%)
11.79
9.49
11.77
8.75
8.97
7.6
7.18
5.66
10.4
7.29
8.38
6.33
6.61
10.35
Profit Margin (%)
4.81
6.61
3.75
2.74
3.35
3.76
4.09
6.02
9.25
11.21
12.38
10.33
10.68
10.03
Working Capital
556
656
621
588
577
538
472
445
544
771
909
856
1,014
1,142
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
20
23
30
28
65
66
Total Equity
940
1,002
997
1,031
1,107
1,146
1,208
1,323
1,488
1,865
2,256
2,450
2,677
2,776
Return on Invested Capital (%)
10.32
11.62
7.31
5.31
8.33
7.55
8.15
11.6
20.56
22.86
24.03
14.79
13.46
11.31
Return on Capital (%)
10.52
11.83
8.53
6.52
8.76
7.25
7.73
11.56
21.18
23.84
24.39
14.76
13.51
11.49
Return on Common Equity (%)
10.72
12.31
8.76
6.48
8.63
7.28
7.81
11.74
21.82
24.43
25.39
15.47
14.13
11.85

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
27
27
27
LT Borrowings
34
34
34
LT Finance Leases
34
33
32
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
153
153
153
Market Capitalization
5,156
3,821
4,120

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,795
2,807
2,798
Cash, Cash Equivalents & STI
1,128
1,042
1,186
Accounts Receivable, Net
909
829
731
Inventories
328
312
292
Total Current Liabilities
1,807
1,703
1,656
Payables & Accruals
- -
- -
- -
ST Debt
27
27
27
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.58%
15.32%
9.24%
Free Cash Flow
137.29%
32.65%
52.54%
Net Income, GAAP
21.65%
27.36%
-0.65%
Sales/Revenue/Turnover
5.11%
7.95%
-3.85%
Total Cash Common Dividend
19.19%
44.25%
-24.73%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
970
1,039
872
624
3,505
2025
892
913
- -
818
3,370
2026
873
738
686
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.65
0.91
0.54
0.26
2.38
2025
0.73
0.72
- -
0.48
2.37
2026
0.58
0.58
0.4
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
1.2
0.01
0.01
1.23
2025
0.01
0.9
- -
0.01
0.93
2026
- -
0.9
- -
- -
- -

Company Description

CEO
Jun Wang
Full Time Employees
2,257
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 484 Parrot Avenue Wuhan HB China 430052
IPO Date
Apr 19, 2004
Website
whjm.com
Business
Jianmin Pharmaceutical Group Co., Ltd. Jianmin Pharmaceutical Group Co., Ltd. (600976.SS) is a China-based company principally engaged in the research, development, manufacturing, wholesale and retail of pharmaceuticals, with a primary focus on pediatric medicines, gynecological medicines and specialty traditional Chinese medicines. The company operates through two main segments: Pharmaceutical Production and Sales, which produces various Chinese patent medicines including flagship products such as Longmuzhuang bone granules for pediatric growth and nutrition, bowel relief capsules, spleen health blood tablets, Xiaojin capsules and pediatric Baotaikang tablets under the Jianmin, Longmu and Yekaitai brands, selling them to distributors, hospitals and pharmacies; and the Commercial segment, which purchases drugs from manufacturers and agents for distribution to lower-level channels, hospitals and retail outlets, alongside over-the-counter (OTC), medical and general health products, as well as traditional Chinese medicine consultation services. Founded in 1993 and headquartered at No. 484 Parrot Avenue, Hanyang District, Wuhan, China, it primarily serves the domestic market with approximately 2,345 employees and maintains a research institute dedicated to pediatric drug development. Recent developments include regulatory approval for a sinusitis drug trial in August 2025, marketing approval for furosemide oral solution, a subsidiary's 12.31 million yuan investment in preprocessing building renovations announced in late 2024, a 6.13% stake acquisition in HeraMED Limited completed in July 2024, and a planned donation of pharmaceuticals worth approximately 1 million yuan to earthquake-affected areas in Tibet in January 2025.